Pigs are important intermediate hosts for generating novel influenza viruses. The Eurasian avian-like H1N1 (EAH1N1) swine influenza viruses (SIVs) have circulated in pigs since 1979, and human cases associated with EAH1N1 SIVs have been reported in several countries. However, the biologic properties of EAH1N1 SIVs are largely unknown. Here, we performed extensive influenza surveillance in pigs in China and isolated 228 influenza viruses from 36,417 pigs. We found that 139 of the 228 strains from pigs in 10 provinces in China belong to the EAH1N1 lineage. These viruses formed five genotypes, with two distinct antigenic groups, represented by A/swine/Guangxi/18/2011 and A/swine/ Guangdong/104/2013, both of which are antigenically and genetically distinct from the current human H1N1 viruses. Importantly, the EAH1N1 SIVs preferentially bound to human-type receptors, and 9 of the 10 tested viruses transmitted in ferrets by respiratory droplet. We found that 3.6% of children (≤10 y old), 0% of adults, and 13.4% of elderly adults (≥60 y old) had neutralization antibodies (titers ≥40 in children and ≥80 in adults) against the EAH1N1 A/swine/Guangxi/18/2011 virus, but none of them had such neutralization antibodies against the EAH1N1 A/swine/ Guangdong/104/2013 virus. Our study shows the potential of EAH1N1 SIVs to transmit efficiently in humans and suggests that immediate action is needed to prevent the efficient transmission of EAH1N1 SIVs to humans.
swine influenza | H1N1 | Eurasian lineage | evolution | pandemic potential P igs play a pivotal role in the ecology of influenza A viruses, being regarded as intermediate hosts for the generation of novel and potentially dangerous influenza viruses for humans. Cellular receptors containing α-2,3-linked sialic acids (Sias) (avian-like receptors) and α-2,6-linked Sias (human-like receptors) in the pig trachea favor the productive replication of viruses from both the avian and mammalian lineages (1) . Influenza viruses of the subtypes H1N1, H1N2, and H3N2 are circulating in pigs globally (2) . Two lineages of H1N1 swine influenza viruses (SIVs), classical H1N1 SIVs and Eurasian avian-like H1N1 (EAH1N1) SIVs, have been circulating in pigs since 1918 and 1979, respectively (3, 4) . The classical H1N1 SIVs emerged in humans as a reassortant (2009/H1N1) and caused the 2009 H1N1 influenza pandemic (5) . The EAH1N1 SIVs have been detected in pigs in many Eurasian countries (6) and have caused several human infections in European countries and also in China (7) (8) (9) (10) (11) , where a fatal case was reported (11) . EAH1N1 SIVs are reported to be most prevalent in pigs that have been brought into Hong Kong since 2005 (12) . However, the evolution and biologic properties of the EAH1N1 SIVs are largely unknown.
China is the largest pork-producing country in the world. Pigs in China are not vaccinated against influenza, and therefore, influenza viruses can spread freely once they are introduced into pig herds. In this study, we performed active surveillance in pigs and found that the EAH1N1 SIVs are predominant in the pig population in China; we further found that the EAH1N1 SIVs pose an imminent threat with regard to their ability to cause a human influenza pandemic. Table  S1 ). EAH1N1 SIVs was detected in ten provinces (SI Appendix, Table S1 and Fig. S1 ). The 2009/H1N1 and H1N2 SIVs were detected in four provinces, respectively, and the classical H1N1, H3N2, and H9N2 SIVs were each detected in only one province (SI Appendix, Table S1 ). These results indicate that the EAH1N1 is the predominant SIV circulating in pigs in China. Conflict of interest statement: Y.K. has received speaker's honoraria from Toyama Chemical and Astellas Inc.; has received grant support from Chugai Pharmaceuticals, Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Inc., and Otsuka Pharmaceutical Co., Ltd; and is a founder of FluGen.
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Genetics of EAH1N1 SIVs. We fully sequenced the genome of 40 representative EAH1N1 SIVs that came from different farms. The HA gene of the 40 SIVs shared 92.7-100% identity at the nucleotide level and formed two phylogenetic groups (Fig. 1A) . The NA gene of these SIVs shared 91.1-100% identity at the nucleotide level and formed three phylogenetic groups (SI Appendix, Fig. S2A ).
The six internal genes of the EAH1N1 SIVs showed distinct diversity, with the basic polymerase 2 (PB2), PB1, acidic polymerase (PA), nucleoprotein (NP), matrix (M), and nonstructural protein (NS) genes of the 40 viruses sharing 82.9-100%, 84.1-100%, 83.7-100%, 82.4-100%, 93.6-100%, and 80.1-100% identity, respectively, at the nucleotide level. The PB2 and NS genes each formed three groups (two of which originated from EAH1N1 and the third from 2009/H1N1) in the phylogenetic trees ( On the basis of this genomic diversity, we divided these EAH1N1 SIVs into five genotypes (Fig. 1B) . The SIVs in genotypes 2 and 5 bear six and five internal genes, respectively, from 2009/H1N1 viruses (Fig. 1B) . The two SIVs in genotypes 4 and 5 have NS genes derived from the North American H1N2 triple reassortant SIVs rather than from the EAH1N1 SIVs (SI Appendix, Fig. S2G ). The genotype 1 SIVs were detected in 10 provinces, whereas the viruses in genotypes 2, 3, 4, and 5 were only detected in one or two provinces (Fig. 1B) .
To understand the biologic properties of these EAH1N1 SIVs, we selected 10 strains (red text in Fig. 1B) , including six SIVs of genotype 1 and one SIV from each of genotypes 2, 3, 4, and 5, and tested their antigenic properties, receptor-binding preference, virulence, and transmissibility in mammals.
Antigenic Analysis. The antigenic match between a vaccine and the circulating viruses is one of the most important factors in determining the efficacy of the vaccine. When the prevalent human influenza viruses show a greater than fourfold difference in hemagglutination inhibition (HI) assay titer from the vaccine strain, the immunity induced by the vaccine does not prevent the circulation of such viruses in humans (13) . We therefore selected ferret antisera against 2009/H1N1 virus A/Sichuan/1/2009 (SC/1/ 09), which is from the current H1N1 human influenza vaccine lineage, and against A/swine/Guangxi/18/2011 (SW/GX/18/11) and A/swine/Guangdong/104/2013 (SW/GD/104/13), which contain the HA of group 1 and 2, respectively, for antigenic analysis.
The antiserum against SC/1/09 cross-reacted with the EAH1N1 SIVs bearing the HA of group 1 and 2 with titers fourto eightfold and 64-128-fold, respectively, lower than the homologous titer. The antiserum against SW/GX/18/11 reacted well with the EAH1N1 SIVs bearing the HA of group 1, but its cross-reactive titers with 2009/H1N1 and the EAH1N1 SIVs bearing the HA of group 2 were fourfold and 32-128-fold, respectively, lower than the homologous titer. The antiserum against SW/GD/104/13 reacted well with the EAH1N1 SIVs bearing the HA of group 2, but its cross-reactive titers with the EAH1N1 SIVs bearing the HA of group 1 and with 2009/H1N1 were 32-64-fold and 128-fold, respectively, lower than the homologous titer (Table 1) . We found 23 amino acid differences in the HA antigenic sites among these viruses (SI Appendix, Table  S2 ). Which amino acid contributes to these observed antigenic differences has yet to be determined. Our results indicate that the EAH1N1 SIVs formed two distinct antigenic groups and both groups show a striking antigenic difference from the 2009/ H1N1 virus.
Receptor-Binding Preference. We tested the receptor-binding specificity of the EAH1N1 SIVs by using a solid-phase binding assay with four different glycans as described previously (14, 15) . The SC/1/09, and an H5N1 virus, A/duck/Anhui/1/2006, were included for comparison. The SC/1/09 and all 10 EAH1N1 SIVs bound to α-2,6-linked Sias with high affinity and to α-2,3-linked Sias with very low affinity (SI Appendix, Fig. S3 A-J and L), whereas the H5N1 virus bound to α-2,3-linked Sias with high affinity and to α-2,6-linked Sias with very low affinity (SI Appendix, Fig. S3K ). These results indicate that the EAH1N1 SIVs preferentially bind to the human-type receptor.
Replication and Virulence in Mice. We investigated the virulence in mice of the EAH1N1 SIVs as described previously (16) . The 10 EAH1N1 SIVs replicated in the lungs of mice, nine SIVs were detected in the nasal turbinate of mice, and two were also detected in the kidneys (SI Appendix, Fig. S4) . No virus was detected in the spleen or brain of any mice. Mice infected with these SIVs lost 7-29.1% of their body weight, and two SIVs, A/swine/Guangdong/30/2013 (SW/GD/30/13) and A/swine/Guangdong/306/2013 (SW/GD/306/13), killed 40% and 60% of the mice, respectively (SI Appendix, Fig. S4 ).
Replication and Transmission of EAH1N1 SIVs in Ferrets. Two ferrets were inoculated intranasally (i.n.) with 10 6.0 50% egg infectious dose (EID 50 ) of each virus, and organs from each ferret were collected on day 4 postinoculation (p.i.) for virus titration in eggs. All 10 of the viruses replicated in the nasal turbinate, tonsils, and trachea of the ferrets (Fig. 2) . Virus was detected in all lung lobes of the ferrets inoculated with six of the viruses (Fig. 2 A, B, D, F , H, and J) but was not detectable in some of the lung lobes of ferrets inoculated with the other four viruses (Fig. 2 C, E, G, and I) . Virus was detected in the kidneys of one ferret inoculated with A/swine/ Hunan/26/2010 (SW/HuN/26), A/swine/Jiangsu/49/2012 (SW/JS/49/ 12), and SW/GD/30/13 ( Fig. 2 A, E, and H) . Virus was also detected in the brain of one ferret in each of the groups that were inoculated with SW/JS/49/12 and A/swine/Tianjin/47/2011 (SW/TJ/ 47/11) (Fig. 2 E and G) and in two ferrets in each of the groups that were inoculated with A/swine/Henan/232/2011 (SW/HeN/232/11) and A/swine/Heilongjiang/27/2012 (SW/HLJ/27/12) (Fig. 2 C  and D) .
Macroscopic lesions were observed in the lungs of ferrets inoculated with all of the SIVs, except for those inoculated with SW/ GD/104/13 ( Fig. 3 A and B) . Pathological studies indicated that most of the lungs showed mild damage after infection with SW/GD/ 104/13 (Fig. 3C) , and viral antigen was not detected (Fig. 3D) . By contrast, the lungs of the other nine virus-infected ferrets showed severe bronchopneumonia (Fig. 3 E-M) , and viral antigen was detected in the epithelial cells of the bronchus and alveoli (Fig. 3N) . Ferrets were inoculated intranasally with 10 6 EID 50 of the indicated virus, and sera were collected 3 wk postinoculation. Homologous titers are underlined and bolded. Respiratory droplet transmission was assessed in ferrets as described previously (15, 16) . The highly transmissible SC/1/09 was included as a control (14, 17) . Virus was detected in all of the directly infected animals (Fig. 4 A-K) . In the exposed groups, virus was not detected in any of the animals exposed to the SW/ GD/306/13-inoculated ferrets (Fig. 4J) , but virus was detected in one ferret exposed to the ferrets that had been inoculated with SW/HuN/26/10, SW/HLJ/27/12, SW/GD/104/13, and SW/GD/30/13 (Fig. 4 A, D , H, and I) and in two ferrets exposed to the ferrets that had been inoculated with SW/JS/49/12 (Fig. 4E) . Importantly, like the 2009/H1N1 SC/1/09 virus (Fig. 4K) , four EAH1N1 SIVs-SW/GX/18/11, SW/HeN/232/11, A/swine/Hunan/30/2013 (SW/HuN/30/13), and SW/TJ/47/11-transmitted to all three exposed ferrets (Fig. 4 B, C, F, and G) . The ferrets that were inoculated with these EAH1N1 SIVs experienced a 0.2-18.6% body weight loss, and the exposed ferrets lost up to 21% of their body weight (Table 2 and SI Appendix, Table S4 ). Seroconversion occurred in all of the virus-inoculated animals and in all exposed animals that were virus-positive (Table 2) .
Human Immunity to the EAH1N1 Viruses. Serum HI antibody titers of 40 (18, 19) , or microneutralization (MNT) antibody titers of 40 in children or at least 80 in adults, are associated with no less than a 50% reduction in risk of infection or disease with influenza viruses in human populations (20) . To investigate whether humans have any existing immune protection against the EAH1N1 SIVs, we tested sera collected from children (<10 y old, n = 55), adults (25-53 y old, n = 52), and elderly adults (≥60 y old, n = 52), against three viruses (SC/1/09, SW/GX/18/11, and SW/GD/104/13) for both HI and MNT antibodies as described previously (20, 21) . We found that only 9.1%, 5.5%, and 0% of the children; 7.7%, 11.5%, and 3.8% of the adults; and 1.9%, 3.8%, and 0% of the elderly adults had HI antibody titers ≥40 to SC/1/09, SW/GX/18/11, and SW/GD/104/13, respectively (SI Appendix, Table S5 ). In addition, 12.7%, 3.6%, and 0% of the children had MNT antibody titers ≥40, and 1.9%, 0%, and 0% of the adults and 0%, 13.4%, and 0% of the elderly adults had MNT antibody titers ≥80 to SC/1/09, SW/GX/18/11, and SW/GD/104/13, respectively (SI Appendix, Table S5 ). These results indicate that the preexisting immunity in the human population may not be able to prevent the spread of the EAH1N1 SIVs.
Discussion
Here, we detected different subtypes of SIVs in pigs in China from 2010 to 2013 and found that the predominant strains are the EAH1N1 SIVs, which have evolved into five different genotypes through accumulated mutations or the acquisition of different internal gene segments from viruses in other lineages. We further determined that the EAH1N1 SIVs have formed two distinct antigenic groups and exhibit markedly different antigenicity from that of the 2009/H1N1 pandemic virus. Most importantly, we found that these SIVs preferentially or exclusively bind human-like receptors and that some of them can transmit efficiently between ferrets by respiratory droplet.
Several amino acid changes in PB2 are important for the replication or virulence of influenza viruses in mammals (22) (23) (24) (25) (26) (27) (28) (29) (30) . A detailed comparison of the amino acid differences among the EAH1N1 SIVs indicated that all of these viruses have mammalian-adapting mutations in their PB2 genes (SI Appendix, Table  S3 ). Therefore, although the EAH1N1 viruses do not cause severe disease in pigs and have different replication and virulence phenotypes in animal models, they may be able to replicate well and possibly cause appreciable disease in humans, as observed during the 2009/H1N1 influenza pandemic (31) .
The human influenza vaccination coverage in China is less than 2% (32). Although we cannot attribute the seropositivity of humans against H1N1 viruses to vaccination or natural infection, the overall seropositive rate to the EAH1N1 SIVs in humans is low. Two doses of the seasonal trivalent inactivated influenza vaccine could not substantially improve the levels of crossreactive antibodies to the EAH1N1 virus in humans (10) . Thus, preexisting immunity in humans may not be sufficient to overcome EAH1N1 SIV infection.
Numerous studies have evaluated the pandemic potential of animal influenza viruses (14-17, 22, 33-39) . Although H5N1 mutants and reassortants have been shown to be transmissible in ferrets or guinea pigs (14, 33, 35, 36) , none of the naturally occurring H5N1 viruses is transmissible via respiratory droplet in these animal models. Certain H7N9 viruses are transmissible in ferrets (15, 40) , but their circulation so far is geographically restricted. The Centers for Disease Control and Prevention in the United States developed a risk assessment tool to evaluate the pandemic potential of different influenza strains (41) . By using this tool, we found that the EAH1N1 SIVs got the highest risk score among six different subtypes of viruses (SI Appendix, Table  S6 ), suggesting that the EAH1N1 SIVs may pose the highest pandemic threat among the influenza viruses currently circulating in animals.
Methods
This study was carried out in accordance with the recommendations in the The detailed methods for this study are provided in SI Appendix. Data shown are from the animal in that group with the maximum body temperature increase or maximum body weight loss. The data for all of the animals in each group are reported in SI Appendix, Table S4 . Seroconversion was confirmed from ferret serum that was collected on day 21 postinoculation.
